New results are in for a trial examining the effectiveness of the anti-estrogen drugs tamoxifen and anastrozole for the prevention of breast cancer recurrence. After 10 years, the results demonstrate that anastrozole (Armidex®) causes fewer side-effects and is better at preventing cancer recurrence than tamoxifen (Nolvadex®, Istubal®, Valodex®). The trial only examined outcomes in post-menopausal women diagnosed with early stage breast cancer.
Tamoxifen works by blocking the binding of estrogn to its receptor and armidex blocks the enzyme that creates estrogen from other molecules.
Top